These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 35858613)

  • 1. [The Cost of Early Diagnosis of Cognitive Decline in German Memory Clinics].
    Onur OA; Wolff-Menzler C; von Arnim CAF; Jessen F; Fink GR; Wiltfang J; Laske C; Schneider A; Levin J; Oberstein T; Kornhuber J; Oberhauser F; Gallinat J; Dodel R; Otto M; Peters O; Teipel S; Duezel E; Riemenschneider M; Flöel A; Perneczky R; Reetz K; Schulz JB; Hausner L; Grimmer T; Frölich L
    Fortschr Neurol Psychiatr; 2022 Jul; 90(7-08):361-367. PubMed ID: 35858613
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost of diagnosing dementia in a German memory clinic.
    Michalowsky B; Flessa S; Hertel J; Goetz O; Hoffmann W; Teipel S; Kilimann I
    Alzheimers Res Ther; 2017 Aug; 9(1):65. PubMed ID: 28830516
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Memory clinics in Germany-structural requirements and areas of responsibility].
    Hausner L; Frölich L; von Arnim CAF; Bohlken J; Dodel R; Otto M; Rapp M; Schulz J; Supprian T; Wollmer MA; Jessen F;
    Nervenarzt; 2021 Jul; 92(7):708-715. PubMed ID: 33025072
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Memory Clinics in Germany - Results of a Hospital Survey].
    Meiberth D; Rapp MA; Jessen F
    Psychiatr Prax; 2019 May; 46(4):213-216. PubMed ID: 30641612
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Costs of diagnosing early Alzheimer's disease in three European memory clinic settings: Results from the precision medicine in Alzheimer's disease project.
    Wimo A; Kirsebom BE; Timón-Reina S; Vromen E; Selnes P; Bon J; Emersic A; Kramberger MG; Speh A; Visser PJ; Winblad B; Fladby T
    Int J Geriatr Psychiatry; 2024 Jul; 39(7):e6126. PubMed ID: 39030788
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation].
    Llorca PM; Miadi-Fargier H; Lançon C; Jasso Mosqueda G; Casadebaig F; Philippe A; Guillon P; Mehnert A; Omnès LF; Chicoye A; Durand-Zaleski I
    Encephale; 2005; 31(2):235-46. PubMed ID: 15959450
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Revenue and losses with vertebral augmentation under the G-DRG system 2012 - a comparison of supply costs in the context of vertebroplasty and kyphoplasty].
    Krüger A; Wollny M; Oberkircher L; Bornemann R; Pflugmacher R
    Z Orthop Unfall; 2012 Oct; 150(5):539-46. PubMed ID: 23076753
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost of illness and its predictors for Parkinson's disease in Germany.
    Spottke AE; Reuter M; Machat O; Bornschein B; von Campenhausen S; Berger K; Koehne-Volland R; Rieke J; Simonow A; Brandstaedter D; Siebert U; Oertel WH; Ulm G; Dodel R
    Pharmacoeconomics; 2005; 23(8):817-36. PubMed ID: 16097843
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of Cerebrospinal Fluid Biomarkers of Alzheimer's Disease Risk in Mild Cognitive Impairment and Subjective Cognitive Decline in Routine Clinical Care in Germany.
    Bartels C; Kögel A; Schweda M; Wiltfang J; Pentzek M; Schicktanz S; Schneider A
    J Alzheimers Dis; 2020; 78(3):1137-1148. PubMed ID: 33104034
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Financing in knee arthroplasty: a benchmarking analysis.
    Effenberger H; Rehart S; Zumstein MD; Schuh A
    Arch Orthop Trauma Surg; 2008 Dec; 128(12):1349-56. PubMed ID: 18309508
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of the Revenue Situation in Interventional Radiology Based on the Example of Peripheral Artery Disease in the Case of a DRG Payment System and Various Internal Treatment Charges.
    Vogt FM; Hunold P; Haegele J; Stahlberg E; Barkhausen J; Goltz JP
    Rofo; 2018 Apr; 190(4):348-358. PubMed ID: 29495050
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Determinants of Medical Direct Costs of Care among Patients of a Memory Center.
    Dauphinot V; Garnier-Crussard A; Moutet C; Delphin-Combe F; Späth HM; Krolak-Salmon P
    J Prev Alzheimers Dis; 2021; 8(3):351-361. PubMed ID: 34101794
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modelling cost effectiveness and cost utility of sequential DMARD therapy including leflunomide in rheumatoid arthritis in Germany: I. Selected DMARDs and patient-related costs.
    Schädlich PK; Zeidler H; Zink A; Gromnica-Ihle E; Schneider M; Straub C; Brecht JG; Huppertz E
    Pharmacoeconomics; 2005; 23(4):377-93. PubMed ID: 15853437
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Bottom-up analysis of the case costs of stem cell transplantation and selected chemotherapies].
    Stäbler W; Wagner B
    Klin Padiatr; 2003; 215(3):179-84. PubMed ID: 12778360
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Healthcare resource utilization and cost in dementia: are there differences between patients screened positive for dementia with and those without a formal diagnosis of dementia in primary care in Germany?
    Michalowsky B; Eichler T; Thyrian JR; Hertel J; Wucherer D; Hoffmann W; Flessa S
    Int Psychogeriatr; 2016 Mar; 28(3):359-69. PubMed ID: 26446797
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Costs of Persons with Dementia Living in Nursing Homes in The Netherlands.
    Klein PCG; Huygens S; Handels R; Wester V; Kanters TA
    J Alzheimers Dis; 2022; 89(1):359-366. PubMed ID: 35871348
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Contribution of leflunomide to the cost effectiveness of sequential DMARD therapy of rheumatoid arthritis in Germany].
    Schädlich PK; Zeidler H; Zink A; Gromnica-Ihle E; Schneider M; Straub C; Brecht JG; Huppertz E
    Z Rheumatol; 2004 Feb; 63(1):59-75. PubMed ID: 14991279
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Economic burden of bilateral neovascular age-related macular degeneration: multi-country observational study.
    Cruess AF; Zlateva G; Xu X; Soubrane G; Pauleikhoff D; Lotery A; Mones J; Buggage R; Schaefer C; Knight T; Goss TF
    Pharmacoeconomics; 2008; 26(1):57-73. PubMed ID: 18088159
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Costs of rheumatoid arthritis in Germany: a micro-costing approach based on healthcare payer's data sources.
    Ruof J; Hülsemann JL; Mittendorf T; Handelmann S; von der Schulenburg JM; Zeidler H; Merkesdal S
    Ann Rheum Dis; 2003 Jun; 62(6):544-9. PubMed ID: 12759292
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Do health-related labour costs weaken the competitiveness of the economy?
    Häussler B; Ecker T; Schneider M
    Pharmacoeconomics; 2006 Dec; 24 Suppl 2():59-68. PubMed ID: 23389489
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.